Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
BL.1.4NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
BA.2.75.9NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BA.2.75.9NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
XBHNUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
XBHNUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
BL.1.2NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BL.1.2NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
BQ.1.1.78NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BQ.1.1.78NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
B.1.9.4NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
B.1.9.4NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
BQ.1.1.64NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BQ.1.1.64NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
XBC.1.2NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
XBC.1.2NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
B.1.221.2NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
B.1.221.2NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
DP.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
DP.1NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
BL.1.5NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BL.1.5NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
BN.2NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BN.2NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
EA.2NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
EA.2NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
XJNUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
XJNUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
BR.5NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BR.5NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
XBF.8NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
XBF.8NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
BA.5.1.29NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BA.5.1.29NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
CM.5.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
CM.5.1NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
BA.5.2.11NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BA.5.2.11NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
BA.2.53NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BA.2.53NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
BA.4.3NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BA.4.3NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
EU.1.1.2NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
EU.1.1.2NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
CM.2.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
CM.2.1NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
XBB.1.43NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
XBB.1.43NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
AY.122.3 (Delta)NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
AY.122.3 (Delta)NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
AY.132 (Delta)NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used